美國用於自體免疫疾病的 IVD 和 LDT 市場規模、佔有率和趨勢分析報告：按類型、技術、應用、國家、細分市場預測，2024-2030 年

美國自體免疫疾病 IVD 與 LDT 市場成長及趨勢：

Grand View Research, Inc.的最新報告顯示，美國自體免疫疾病IVD和LDT市場預計2024年至2030年複合年成長率為4.8%，到2030年將達到37億美元。

自體免疫疾病的高盛行率、對這些疾病的認知不斷提高、對技術開發和高性能產品的需求不斷增加以及對研究的高投資是推動市場成長的因素。

這些健康問題是美國慢性病的第二大原因，也是美國女性死亡的主要原因之一。這些疾病對患者的勞動生產力和生活品質產生負面影響，並造成經濟負擔，對美國的醫療費用支出重大影響。美國國立衛生美國估計，與這些疾病相關的直接醫療費用約為 1,000 億美元，其中癌症醫療費用達到 570 億美元。

在美國，受這些疾病影響的人數眾多，其盛行率以驚人的速度上升，導致醫療費用增加，這些都是優先事項，因此預計將推動成長。此外，此類健康疾病導致的併發症，如內臟器官損傷、運動能力下降和死亡風險，使得此類疾病的早期診斷和介入極為重要。人們對這種情況的認知不斷提高預計將推動市場成長。

許多研究人員認為，全球自體免疫疾病的增加是由於遺傳傾向和環境因素造成的。然而，人們對於環境中什麼因素引發自體免疫疾病的了解卻甚少。

儘管FDA將體外診斷作為醫療設備進行監管，但過去並無權監管LDT。隨後，FDA宣布將利用醫療設備監管權限對LDT進行監管。一些研究人員認為 FDA 對 LDT 的監管將增加測試開發的時間和成本。

美國自體免疫疾病 IVD 和 LDT 市場報告亮點

• 2023年，類風濕性關節炎IVD將成為主要細分市場，收益佔有率12.14%，類風濕性關節炎LDT佔有率為11.47%。類風濕性關節炎的高盛行率以及大量可用的診斷測試促進了市場佔有率的成長。
• 2023年，臨床化學成為領先細分領域，IVD市佔率為32.37%，LDT市佔率為19.98%。血液中自體抗體的診斷是最常見的診斷方法，因此佔有很大的市場佔有率。
• 預計克隆氏症在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國自體免疫疾病 IVD 和 LDT 市場變數、趨勢和範圍

• 市場介紹/系統展望
• 市場規模及成長前景
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 美國自體免疫疾病IVD和LDT市場分析工具
  • 波特的分析
  • PESTEL分析

第4章美國自體免疫疾病IVD和LDT市場：按類型估計和趨勢分析

• 細分儀表板
• 美國自體免疫疾病 IVD 和 LDT 市場：2023 年和 2030 年按類型變化分析
• 體外診斷
• LDDT

第5章美國自體免疫疾病IVD和LDT市場：技術估算和趨勢分析

• 細分儀表板
• 美國自體免疫疾病 IVD 和 LDT 市場：2023 年和 2030 年技術變化分析
• 免疫檢測
• 臨床化學
• 血液學
• 凝固
• 微生物學
• 分子診斷
• 其他

第6章美國自體免疫疾病IVD和LDT市場：按應用估算和趨勢分析

• 細分儀表板
• 美國自體免疫疾病 IVD 和 LDT 市場：2023 年和 2030 年按應用分類的變化分析
• 愛迪生氏症
• 僵直性脊椎炎
• 脫髮症
• 類風濕性關節炎
• 全身性紅斑性狼瘡
• 系統性硬皮症
• 乾癬
• 抗磷脂抗體症候群
• 1型糖尿病
• 克隆氏症
• 潰瘍性大腸炎
• 發作性睡病
• 多發性硬化症
• 葡萄膜炎

第7章 競爭格局

• 主要市場參與企業的最新趨勢和影響分析
• 公司分類
• 企業熱力圖分析
• 公司簡介
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Johnson &Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

U.S. IVD And LDT For Autoimmune Diseases Market Growth & Trends:

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.70 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights:

• In 2023, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 12.14% and the LDT for rheumatoid arthritis had a share of 11.47%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
• In 2023, clinical chemistry was the leading segment with a market share of 32.37% in the IVD and 19.98% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
• Crohn's disease is projected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. IVD & LDT for Autoimmune Diseases Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. U.S. IVD & LDT for Autoimmune Diseases Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. IVD & LDT for Autoimmune Diseases Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. IVD & LDT for Autoimmune Diseases Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
• 4.3. IVD
  • 4.3.1. IVD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. LDT
  • 4.4.1. LDT Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
• 5.3. Immunoassays
  • 5.3.1. Immunoassays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Clinical Chemistry
  • 5.4.1. Clinical Chemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Hematology
  • 5.5.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.6. Coagulation
  • 5.6.1. Coagulation Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Microbiology
  • 5.7.1. Microbiology Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. Molecular Diagnostics
  • 5.8.1. Molecular Diagnostics Machine Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.9. Other
  • 5.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. IVD & LDT for Autoimmune Diseases Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. IVD & LDT for Autoimmune Diseases Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
• 6.3. Addison's Disease
  • 6.3.1. Addison's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Ankylosing Spondylitis
  • 6.4.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Alopecia Areata
  • 6.5.1. Alopecia Areata Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Rheumatoid Arthritis
  • 6.6.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.7. Systemic Lupus Erythematosus
  • 6.7.1. Systemic Lupus Erythematosus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.8. Systemic Sclerosis
  • 6.8.1. Systemic Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.9. Psoriasis
  • 6.9.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.10. Antiphospholipid Antibody Syndrome
  • 6.10.1. Antiphospholipid Antibody Syndrome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.11. Diabetes Type 1
  • 6.11.1. Diabetes Type 1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.12. Crohn's Disease
  • 6.12.1. Crohn's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.13. Ulcerative Colitis
  • 6.13.1. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.14. Narcolepsy
  • 6.14.1. Narcolepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.15. Multiple Sclerosis
  • 6.15.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.16. Uveitis
  • 6.16.1. Uveitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Adaptive Biotechnologies Corporation
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. Agilent Technologies Inc.
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Bio-Rad Laboratories, Inc.
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. bioMerieux, Inc.
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Corgenix, Inc.
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Johnson & Johnson Services, Inc.
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Microbix Biosystems Inc.
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. PerkinElmer, Inc.
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. SQI Diagnostics Inc.
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. Thermo Fisher Scientific Inc.
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/ Strategic Initiatives